Here, we show that in preclinical models of CMT1A, the dosed administration of siRNA PMP22-SQ NPs normalizes Pmp22 levels, improves motor and neuromuscular activities, restores electrophysiological endpoints and triggers the remyelination and regeneration of axons. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.